Publications Directly Arising from India Alliance Funded Project:
Nikhil Patkar*, Rohan Kodgule , Chinmayee Kakirde , Goutham Raval , Prasanna Bhanshe , Swapnali Joshi , Shruti Chaudhary , Yajamanan Badrinath , Sitaram Ghogale , Shraddha Kadechkar , Syed Hasan Khizer , Sadhana Kannan , Dhanalaxmi Shetty , Anant Gokarn , Sachin Punatkar , Hasamukh Jain , Bhausaheb Bagal , Hari Menon , Manju Sengar , Navin Khattry , Prashant Tembhare , P.G. Subramanian , Sumeet Gujral. Clinical impact of measurable residual disease monitoring by ultradeep next generation sequencing in NPM1 mutated acute myeloid leukemia. Oncotarget. 2018; 9:36613-36624.
Nikhil Patkar*, Chinmayee Kakirde, Prasanna Bhanshe, Swapnali Joshi, Shruti Chaudhary, Y Badrinath, Sitaram Ghoghale, Nilesh Deshpande, Shraddha Kadechkar, Gaurav Chatterjee, Sadhana Kannan, Dhanalaxmi Shetty, Anant Gokarn, Sachin Punatkar, Avinash Bonda, Lingaraj Nayak, Hasmukh Jain, Bhausaheb Bagal, Hari Menon , Manju Sengar, Syed Hasan Khizer, Navin Khattry, Prashant Tembhare, Sumeet Gujral, Papagudi Subramanian. Utility of Immunophenotypic Measurable Residual Disease in Adult Acute Myeloid Leukemia –Real World Context.Front Oncol. 2019 Jun 13;9:450
Ultradeep Error Corrected Next-generation Sequencing (NGS) of ABL1 Kinase Domain Mutations in BCR-ABL1 Positive Malignancies. Nikhil Patkar and colleagues. Presented at the Annual Meeting of Association for Molecular Pathology AMP 2018, San Antonio, Texas, USA
Tembhare PR, Subramanian Pg PG, Ghogale S, Chatterjee G, Patkar NV, Gupta A, Shukla R, Badrinath Y, Deshpande N, Narula G, Rodrigues P, Girase K, Dhaliwal D, Prasad M, Shetty D, Banavali S, Gujral S .A High-Sensitivity 10-Color Flow Cytometric Minimal Residual Disease Assay in B-Lymphoblastic Leukemia/Lymphoma Can Easily Achieve the Sensitivity of 2-in-106 and Is Superior to Standard Minimal Residual Disease Assay: A Study of 622 Patients.Cytometry B Clin Cytom. 2019 Jun 14. doi: 10.1002/cyto.b.21831.
Rabade N, Subramanian PG, Kodgule R, Raval G, Joshi S, Chaudhary S, Mascarenhas R, Tembhare P, Gujral S, Patkar N. Molecular genetics of BCR-ABL1 negative myeloproliferative neoplasms in India.Indian J Pathol Microbiol. 2018 Apr-Jun;61(2):209-213.
Bibi A, Java S , Chaudhary S , Joshi S , Mascerhenas R , Rabade N , Tembhare P , Subramanian PG , Gujral S , Menon H , Khattry N , Sengar M , Bagal B , Jain H , Patkar N. BRAFV600E mutation in hairy cell leukemia: A single-center experience. Indian J Pathol Microbiol. 2018 Oct-Dec;61(4):532-536.
Nikhil Rabade, Goutham Raval, Shruti Chaudhary, PG Subramanian, Rohan Kodgule, Swapnali Joshi, Prashant Tembhare, Hasmukh Jain, Manju Sengar, Syed Hasan K, Pratibha Amare Kadam, Dhanalaxmi Shetty, Gaurav Narula, Shripad Banavali, Sumeet Gujral, Nikhil Patkar. Molecular heterogeneity in acute promyelocytic leukemia - a single centre experience from India. Mediterr J Hematol Infect Dis. 2018
Tembhare PR, Ghogale S, Tauro W, Badrinath Y, Deshpande N, Kedia S, Cherian K, Patkar NV, Chatterjee G, Gujral S, Subramanian PG. Evaluation of CD229 as a new alternative plasma cell gating marker in the flow cytometric immunophenotyping of monoclonal gammopathies. Cytometry B Clin Cytom. 2018 Jan 9. doi: 10.1002/cyto.b.21619.
Khattry N, Laskar S, Sengar M, Rangarajan V, Shet T, Subramanian PG, Epari S, Bagal B, Goda JS, Agarwal A, Jain H, Tembhare P, Patkar N, Khanna N, Punatar S, Gokarn A, Shetty D, Jain H, Bonda A, Gota V, Hasan S, Kode J, Dutt S, Kulkarni S, Shetty N, Sable N, Deodhar J, Jadhav S, Pawaskar P, Mathew L, Menon H, Nair R, Kannan S, Chiplunkar S, Gujral S. Long term clinical outcomes of adult hematolymphoid malignancies treated at Tata Memorial Hospital: An institutional audit. Indian J Cancer. 2018 Jan-Mar;55(1):9-15. doi: 10.4103/ijc.IJC_656_17.
Narula G, Prasad M, Jatia S, Subramanian PG, Patkar N, Tembhare P, Shetty D, Khanna N, Laskar S, Shet T, Epari S, Kembhavi S, Shah S, Qureshi S, Gujral S, Banavali SD. Clinicoepidemiological profiles, clinical practices, and the impact of holistic care interventions on outcomes of pediatric hematolymphoid malignancies - A 7-year audit of the pediatric hematolymphoid disease management group at Tata Memorial Hospital. Indian J Cancer. 2017 Oct-Dec;54(4):609-615. doi: 10.4103/ijc.IJC_487_17.
Patkar N, Subramanian PG, Tembhare P, Mandalia S, Chaterjee G, Rabade N, Kodgule R, Chopra K, Bibi A, Joshi S, Chaudhary S, Mascerhenas R, Kadam-Amare P, Narula G, Arora B, Banavali S, Gujral S. An integrated genomic profile that includes copy number alterations is highly predictive of minimal residual disease status in childhood precursor B-lineage acute lymphoblastic leukemia. Indian J Pathol Microbiol. 2017 Apr-Jun;60(2):209-213. doi: 10.4103/IJPM.IJPM_466_16.
Nikhil Patkar, Nikhil Rabade, Pratibha Amare Kadam, Falguni Mishra, Aditi Muranjan, Prashant Tembhare, Shruti Chaudhary, Swapnali Joshi, Hasmukh Jain, Uma Dangi, Bhausaheb Bagal, Navin Khattry, Hari Menon, Sumeet Gujral, Manju Sengar, PG Subramanian. Immunogenetics of Chronic Lymphocytic Leukemia. Indian J Pathol Microbiol. 2017 Jan-Mar;60(1):38-42.
Ghodke KA, Patkar NV, Subramanian PG, Gujral S, Kadam PA, Tembhare PR. Biclonal chronic lymphocytic leukemia: A study of two cases and review of literature. Indian J Pathol Microbiol. 2017 Jan-Mar;60(1):84-86. doi: 10.4103/0377-4929.200019.
Nikhil Patkar, Kiran Ghodke, Swapnali Joshi et al. Characteristics of BCR-ABL1 Kinase domain mutations in chronic myeloid leukemia from India: Not just missense mutations but insertions and deletions are also associated with TKI resistance Leuk Lymphoma. 2016 Mar 21:1-8.
Nikhil Patkar, Swapnali Joshi, Shruti Chaudhary et al. Development of a cost effective “duplexed” real time PCR assay for minimal residual disease monitoring of chronic myeloid leukemia using locked nucleic acid probes. Int J Lab Hematol. 2016 Jul 27. doi: 10.1111/ijlh.12541.
Tembhare PR, Ghogale S, Ghatwai N, Badrinath Y, Kunder N, Patkar NV, Bibi AR, Chatterjee G, Arora B, Narula G, Banawali S, Deshpande N, Amare P, Gujral S, Subramanian PG. Evaluation of new markers for minimal residual disease monitoring in B-cell precursor acute lymphoblastic leukemia: CD73 and CD86 are the most relevant new markers to increase the efficacy of MRD assay. Cytometry B Clin Cytom. 2016 Oct 7. doi: 10.1002/cyto.b.21486.
Ghodke K, Bibi A, Rabade N, Patkar N, Subramanian PG, Aamre Kadam P, Badrinath Y, Ghogale S, Gujral S, Tembhare P. CD19 Negative Precursor B Acute Lymphoblastic Leukemia (B?ALL)?immunophenotypic challenges in diagnosis and monitoring: A study of three cases. Cytometry B Clin Cytom. 2016
Tembhare P, Badrinath Y, Ghogale S, Patkar N, Dhole N, Dalavi P, Kunder N, Kumar A, Gujral S, Subramanian PG. A novel and easy FxCycle™ violet based flow cytometric method for simultaneous assessment of DNA ploidy and six-color immunophenotyping. Cytometry A. 2016 Mar;89(3):281-91.
Patkar N, Subramanian PG, Deshpande P, Ghodke K, Tembhare P, Mascarenhas R, Muranjan A, Chaudhary S, Bagal B, Gujral S, Sengar M, Menon H. MYD88 Mutant Lymphoplasmacytic Lymphoma / Waldenstroms Macroglobulinemia has distinct clinical and pathological features as compared to its mutation negative counterpart. Leuk Lymphoma. 2015 Feb;56(2):420-5. doi: 10.3109/10428194.2014.924123